Compare F.N.B. Corporation Common Stock (FNB) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Halozyme Therapeutics Inc. Common Stock — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while Halozyme Therapeutics Inc. Common Stock trades at $117.12 (market cap $12.44B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays a 3.05% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| FNB | HALO | |
|---|---|---|
Market Cap | $6.07B | $12.44B |
Volume | 5,600,609 | 1,772,623 |
Sector | Financials | Health |
52-Week High | $19.49 | $116.82 |
52-Week Low | $14.65 | $61.63 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $10.61B | $14.36B |
Dividend Yield | 3.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Halozyme Therapeutics (HALO) trades at $109.62, down 1.31% today but near its recent highs. The stock shows strong fundamental momentum with revenue growth from $1.4B in 2025 to $1.7B projected for 2026 and net income margins improving to 24.85%. Recent positive developments include a patent win against Merck in Europe and an expanded collaboration with argenx, enhancing its ENHANZE technology revenue streams. Technical indicators are bullish on moving averages, though oscillators signal neutrality with RSI at 73 suggesting overbought conditions. Support is firm at $107 with resistance at $112.
HALO presents a growth opportunity driven by robust financials and strategic expansions, but risks include high valuation multiples (P/E 32.15, P/B 86.68) and insider selling by the CEO. Analyst consensus is strongly bullish with 66.7% buy ratings and a $106 price target, though the current price exceeds this, indicating potential near-term consolidation. Investors should weigh solid earnings beats against elevated expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
